http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20110078671-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_799b6c8cb40ea97102dceda7bfe7b5c7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2561-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2009-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85548933d04856134e90dfe3f68ce574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_564f99e82de82418970e91ac294c42a3 |
| publicationDate | 2011-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20110078671-A |
| titleOfInvention | Method and kit for predicting therapeutic reactivity of vascular endothelial growth factor specific tyrosine kinase inhibitor |
| abstract | The present invention provides a method and kit for predicting vascular endothelial growth factor-specific tyrosine kinase inhibitor treatment responsiveness to apply a selective vascular endothelial growth factor-specific tyrosine kinase inhibitor (VEGF-Specific TKI) therapy according to the patient. It's about. When using the method and kit for predicting vascular endothelial growth factor-specific tyrosine kinase inhibitor treatment reactivity by identifying and evaluating methylation of the vascular endothelial growth factor receptor gene promoter according to the present invention, Effectively, patients subject to vascular endothelial growth factor-specific tyrosine kinase inhibitor (VEGF-Specific TKI) therapy can be screened, thereby reducing the economic, psychological, and physical pain of patients with indiscriminate therapy. |
| priorityDate | 2009-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 228.